Janux Therapeutics (JANX) Operating Margin (2021 - 2026)
Janux Therapeutics (JANX) posted quarterly Operating Margin of 916.5% for Q1 2026, down 159.99% quarter-over-quarter from 352.51% in Q3 2025.
Powered by 
Analysis
Janux Therapeutics (JANX) Operating Margin (2021 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Operating Margin for 6 consecutive years, with 916.5% the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Margin changed N/A year-over-year to 916.5%; the TTM figure through Mar 2026 stood at 1143.11% (up 7351.0% YoY), while the FY2025 annual figure was 1576.67%, down 64309.0% from the prior year.
- Operating Margin eased to 916.5% in Q1 2026 per JANX's latest filing, from 352.51% in the prior quarter.
- Across five years, Operating Margin topped out at 155.36% in Q2 2024 and bottomed at 8164.46% in Q3 2024.
- Historically, Operating Margin has averaged 1434.96% across 5 years, with a median of 852.23% in 2022.
- Annual changes were most pronounced in 2024 — Operating Margin tumbled 753622 bps — and 2025, when it soared 781195 bps.
- Janux Therapeutics' Operating Margin stood at 642.04% in 2022, then slipped by 2 bps to 655.71% in 2023, then slumped by 1145 bps to 8164.46% in 2024, then soared by 96 bps to 352.51% in 2025, then slumped by 160 bps to 916.5% in 2026.
- Business Quant data shows JANX's Operating Margin at 916.5% in Q1 2026, 352.51% in Q3 2025, and 8164.46% in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Janux Therapeutics | 1.27 Bn | 1.27 Bn | - | -308.66% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -308.66% |
| Mar 31, 2026 | -916.50% |
| Sep 30, 2025 | -352.51% |
| Sep 30, 2024 | -8,164.46% |
| Jun 30, 2024 | -155.36% |
| Mar 31, 2024 | -1,610.30% |
| Dec 31, 2023 | -655.71% |
| Sep 30, 2023 | -628.25% |
| Jun 30, 2023 | -1,962.91% |
| Mar 31, 2023 | -990.28% |
| Dec 31, 2022 | -642.04% |
| Sep 30, 2022 | -994.04% |
| Jun 30, 2022 | -729.85% |
| Mar 31, 2022 | -852.23% |
| Dec 31, 2021 | -834.78% |
| Sep 30, 2021 | -940.72% |
| Jun 30, 2021 | -1,297.10% |
| Mar 31, 2021 | -601.05% |